From Yahoo Finance: 2025-06-14 08:40:00

Oppenheimer raised Ascendis Pharma’s price target to $224 and maintains an Outperform rating. A survey of 20 U.S. endocrinologists shows strong early demand for Yorvipath, with 20%-30% of hypoPT patients expected to be on the drug in a year. 90% of surveyed physicians would use Yorvi to preserve kidney function. Access/reimbursement is seen as the main adoption hurdle, but Oppenheimer believes Yorvi’s successful U.S. launch will surpass expectations. (Source: TheFly)

For more information on ASND, you can check out the top stocks recommended by analysts. (Source: TipRanks)



Read more at Yahoo Finance: Ascendis Pharma price target raised to $224 from $215 at Oppenheimer